The effects of high-sensitivity C-reactive protein on the clinical outcomes in obstructive sleep apnea patients undergoing off-pump coronary artery bypass grafting

Mingxin Gao1, Kangjun Fan1, Wenyuan Yu1, Hongli Liu1, Yongxiang Wei2 and Yang Yu1*

Abstract
Purpose: To investigate the relationship between obstructive sleep apnea (OSA) severity and high-sensitivity C-reactive protein (Hs-CRP), and their respective impact on the clinical outcomes in patients undergoing off-pump cardiac artery bypass grafting (OPCABG).

Methods: We enrolled consecutive eligible patients listed for elective OPCABG who underwent cardiorespiratory polygraphy before surgery between January 2019 and December 2019 in this prospective observational single-center study. Baseline, intraoperative, and postoperative clinical data were compared between absent-mild and moderate-severe OSA groups. Regression analysis investigated the relationship between Hs-CRP level and severity of OSA, and further assessed the factors influencing postoperative atrial fibrillation, duration of hospitalization, and hospital cost.

Results: Patients with moderate-severe OSA accounted for 42.3% (52/123) of the cohort. Partial pressure of carbon dioxide (PCO2), Hs-CRP, apnea hypopnea index (AHI), mean apnea time, maximum apnea time, and oxygen desaturation index ODI ≥ 3% were significantly higher in the moderate-severe OSA group than in the absent-mild OSA group. Left ventricle ejection fraction (LVEF), lowest arterial oxygen saturation (SaO2), and mean SaO2 were significantly lower in the moderate-severe OSA group. Moderate-severe OSA was associated with elevated Hs-CRP level (OR = 2.356, 95% CI 1.101–5.041, P = 0.027). Hs-CRP was an independent risk factor for post-CABG atrial fibrillation (POAF) (OR = 1.212, P = 0.01). Hs-CRP level independently correlated with duration of hospitalization (B = 0.456, P = 0.001) and hospital cost (B = 1.111, P = 0.044).

Conclusion: Hs-CRP level was closely related to OSA severity and has potential utility in predicting POAF, duration of hospitalization, and hospital costs in patients undergoing OPCABG.

Keywords: Obstructive sleep apnea, High-sensitivity C-reactive protein, Clinical outcomes, Off-pump cardiac artery bypass grafting

Introduction
Obstructive sleep apnea (OSA) has an incidence of 9–38% in adults and is characterized by repeated or partial obstruction of the respiratory tract during sleep [1]. Intermittent hypoxia induced by OSA could trigger oxidative stress and damage to the vascular endothelium, therefore, it is an independent risk factor for...
coronary heart disease (CHD) and affects its prognosis [2]. Currently, off-pump cardiac artery bypass grafting (OPCABG) has become one of the primary treatments of CHD [3]. However, there were few reports on the relationship between OSA and post-OPCABG complications, in addition, traditional OSA severity markers, such as apnea hypopnea index (AHI), has limitations in predicting the prognosis of CABG [4].

High-sensitivity C-reactive protein (Hs-CRP) is a classical marker of inflammatory response, which has been proven to be central to the pathogenesis of vascular diseases in the context of OSA. A slight increase in Hs-CRP level could indicate coronary plaque inflammation or coronary artery wall injury, which is closely related to CHD and its associated negative events [5].

In this study, we aimed to investigate the relationship between the severity of OSA and Hs-CRP, and their respective impact on the clinical outcomes in patients undergoing OPCABG during hospitalization.

Methods
Study design
This prospective observational single-center study was conducted at the Beijing Anzhen Hospital, Capital Medical University. We enrolled consecutive patients with coronary artery disease who were scheduled to undergo elective OPCABG and had not been diagnosed with OSA from January 2019 to December 2019. The study protocol, which was approved by the institutional review board (Approval No.: 2013025), was explained to all patients, all of whom signed informed consent for sleep monitoring tests (polygraphy, PG).

Patients
All participating patients, aged between 40 and 75 years old, underwent an overnight sleep study before OPCABG. We excluded patients with valvular disease combined with other heart diseases, central sleep apnea, severe respiratory diseases (e.g., chronic obstructive pulmonary disease), severe diseases of other organs (e.g., renal failure), body temperature > 37.5 °C, and preoperative use of morphine and its analogs, sedative drugs, and/or theophylline. We recorded baseline clinical data, including age, sex, body mass index (BMI), body temperature, pre-existing medical conditions (hypertension, diabetes, stroke), history of smoking, blood biochemistry findings, and left ventricular ejection fraction (LVEF) bases on echocardiography, and PG test data.

PG tests and diagnostic criteria for OSA
Eligible patients were enrolled and admitted to the hospital. PG was performed before OPCABG. Each patient in the sleep monitoring center at Beijing Anzhen Hospital wore a portable sleep monitor (ApneaLink, ResMed, Australia). We used type III PG to detect airflow by nasal catheter, respiratory movement by chest belt, heart rate by electrocardiograph, and arterial oxygen saturation (SaO2) by pulse oximetry. All PG test data were analyzed by two physicians at the Sleep Center of Beijing Anzhen Hospital. In case of disagreement between the two, a third physician participated in the data analysis. Sleep apnea was defined as the cessation of airflow through the nose and mouth for > 10 s during sleep; hypopnea, a reduction of > 50% in the airflow intensity and ≥ 4% in SaO2 level during sleep. AHI was defined as the total number of apnea or hypopnea episodes per hour during sleep (i.e., AHI = total number of apnea or hypopnea episodes/total sleep duration (min) × 60). Moderate-severe OSA was defined as an AHI ≥ 15/h during a 7- h sleep. Oxygen desaturation index (ODI) ≥ 3% is the number of times that oxygen saturation decreases by > 3% per hour [6]. All moderate-severe patients were recommended for continuous positive airway pressure (CPAP) after discharge.

OPCABG
All patients underwent OPCABG after the PG test. The same cardiac surgeon performed all surgeries. The number of grafts and surgical duration were recorded. The quality of graft anastomosis met the criteria recommended by the Operation Quality Committee of Beijing Anzhen Hospital. Two ultrasound specialists performed echocardiography in all patients, and a single nurse measured the blood pressure and collected blood samples from the patients. After surgery, the patients were monitored in the intensive care unit (ICU) until ventilator removal was feasible and vital signs were stable; they were discharged from the hospital once they could move freely. The physician in the ICU and the cardiac surgeon determined the ICU stay and hospitalization duration. We recorded the following postoperative data during hospitalization: incidence of major adverse cardiac and cerebrovascular event (MACCE), lung infection, post-CABG atrial fibrillation (POAF); duration of postoperative tracheal intubation; ICU stay; duration of hospitalization, and hospital cost. POAF was defined as the occurrence of AF within 72 h after surgery. Pulmonary infection was defined as a postoperative increase in white blood cell count, obvious inflammation based on postoperative chest radiography and computed tomography, and meeting one of the following conditions: sputum examination reveals new characteristic changes and pathogenic bacteria could be cultivated from blood or respiratory secretions.
Blinding
The cardiac surgeon, other participating investigators, and research staff were blinded to the findings of the PG tests. After the final enrolled patient was discharged from the hospital in January 2020, all data were revealed to the participating investigators.

Statistical analysis
All statistical analyses were performed using SPSS, version 24.0 (SPSS Inc., Chicago, IL, USA). Continuous variables with a normal distribution were presented as means ± standard deviations and were compared using independent samples t-tests. Continuous variables without a normal distribution were presented as medians (interquartile ranges) and were compared using rank-sum tests. Categorical variables are presented as percentages and were compared using χ² tests. If the missing quantity of measurement data was < 5%, the average value was used to replace the missing value. No missing values in the counting data were noted. Logistic regression analysis was implemented to investigate the relationship between Hs-CRP level (dependent variable) and severity of OSA. To analyze the association between preoperative relevant indicators and POAF, duration of hospitalization and hospital cost, multivariate logistic (dependent variable: POAF) and multiple linear regression analysis (dependent variable: duration of hospitalization and hospital cost) were implemented (sex, age, BMI, hypertension, diabetes, AHI and variables with P<0.1 in the univariate logistic or simple linear regression were included in the model). Two-sided P values < 0.05 were considered statistically significant.

Results
Baseline data line characteristics
The study flow chart is shown in Fig. 1. One-hundred-and-seventy-five patients underwent PG and OPCABG from January 2019 to December 2019. A total of 123 patients were included in the final analysis. Based on the PG findings, 71 patients had an AHI < 15 and were assigned to the absent-mild OSA group, while the remaining 52 had an AHI ≥ 15 and were assigned to the moderate-severe OSA group. We set the threshold Hs-CRP level at 2 mg/L, which is according to the results of previous large clinical trials [5]. Seventy-eight patients had an Hs-CRP level of < 2 mg/L and were assigned to the normal Hs-CRP group; 45 had an Hs-CRP level of ≥ 2 mg/L and were assigned to the elevated Hs-CRP group.

---

**Fig. 1** Flow chart showing the inclusion of patients in this study

- Enrollment: 175 Patients
- Exclusion: 52 patients
  - 6 renal insufficiency
  - 7 pulmonary insufficiency
  - 5 body temperature > 37.5°C
  - 6 arrhythmia history
  - 11 central sleep apnea
  - 4 sedatives within 48h
  - 13 combined valve disease
- Participated in the study: 123 patients
- According to OSA
  - Absent-mild OSA: 71 Patients
  - Moderate-severe OSA: 52 Patients
- According to Hs-CRP
  - Normal Hs-CRP: 78 Patients
  - Elevated Hs-CRP: 45 Patients
Preoperative clinical data of the absent-mild OSA and moderate-severe OSA groups were compared (Table 1): partial pressure of carbon dioxide (PCO2, 37.1 ± 4.4 vs. 35.5 ± 3.2 mmHg, \( P = 0.033 \)), Hs-CRP (2.0 [0.7, 6.8] vs. 1.1 [0.3, 2.2] mg/L, \( P = 0.001 \)); Fig. 2), AHI (28.5 ± 11.5 vs. 7.1 ± 4.1 events/h, \( P < 0.001 \)), mean apnea time (40 [31, 61] vs. 27 [19, 35] s, \( P < 0.001 \)), and ODI ≥ 3% (23.3 [18.4, 31.1] vs. 6.1 [3.0, 9.3] s, \( P < 0.001 \)), were significantly higher in the moderate-severe OSA group than in the absent-mild OSA group. LVEF (55.9 ± 9.8 vs. 59.5 ± 8.5, \( P < 0.001 \)), lowest SaO2 (81.6 ± 5.8 vs. 87.0 ± 3.7, \( P < 0.001 \)) and mean SaO2 (93.0 ± 2.4 vs. 95.4 ± 2.1, \( P < 0.001 \)) were significantly lower in the moderate-severe OSA group than in the absent-mild OSA group. No significant difference in other preoperative indexes was found. In addition, the number of grafting performed, duration of surgery, MACCEs, lung infection, POAF, duration of ventilator use, ICU stay, duration of hospitalization, and hospital cost were not significantly different between the two OSA groups (Table 2).

### Table 1: Baseline clinical data for patients with obstructive sleep apnea (OSA) undergoing off-pump coronary artery bypass grafting (OPCABG)

|                          | Absent-mild OSA (n = 71) | Moderate-severe OSA (n = 52) | P value | Total (n = 123) |
|--------------------------|--------------------------|-----------------------------|---------|----------------|
| **Sex (male/female)**    | 55/16                    | 39/13                       | 0.750   | 94/29          |
| **Age (years)**          | 61.3 ± 9.3               | 62.9 ± 8.2                  | 0.334   | 62.0 ± 8.88    |
| **BMI (kg/m²)**          | 25.5 ± 3.2               | 25.2 ± 3.7                  | 0.602   | 25.4 ± 3.4     |
| **Body temperature (°C)**| 36.4 ± 0.4               | 36.3 ± 0.4                  | 0.236   | 36.3 ± 0.4     |
| **Hypertension, n (%)**  | 49 (69)                  | 40 (77)                     | 0.333   | 89 (72)        |
| **Diabetes, n (%)**      | 27 (38)                  | 24 (46)                     | 0.366   | 51 (42)        |
| **ACS, n (%)**           | 61 (86)                  | 41 (79)                     | 0.303   | 102 (83)       |
| **Smoking history, n (%)**| 33 (47)                  | 28 (54)                     | 0.419   | 61 (50)        |
| **Previous stroke, n (%)**| 9 (13)                   | 2 (4)                       | 0.090   | 11 (9)         |
| **Previous AF, n (%)**   | 3 (4)                    | 4 (8)                       | 0.412   | 7 (6)          |
| **Blood test data**      |                          |                             | **P value** |               |
| **PO2 (mmHg)**           | 94.2 ± 18.2              | 88.9 ± 25.5                 | 0.183   | 92.0 ± 21.7    |
| **Hs-CRP (mg/L)**        | 1.1 (0.3, 2.2)           | 2.0 (0.7, 6.8)              | 0.001*  | 1.4 (0.5, 3.5) |

#### Echocardiography data

|                         | Absent-mild OSA (n = 71) | Moderate-severe OSA (n = 52) | P value | Total (n = 123) |
|-------------------------|--------------------------|-----------------------------|---------|----------------|
| **LVEF (%)**            | 59.5 ± 8.5               | 55.9 ± 9.8                  | 0.034*  | 58.0 ± 9.2     |
| **LVDD (mm)**           | 48.9 ± 6.7               | 50.0 ± 5.9                  | 0.326   | 49.4 ± 6.4     |
| **LAD (mm)**            | 36.7 ± 3.8               | 37.0 ± 4.2                  | 0.645   | 36.9 ± 4.0     |

#### PG test data

|                     | Absent-mild OSA (n = 71) | Moderate-severe OSA (n = 52) | P value | Total (n = 123) |
|---------------------|--------------------------|-----------------------------|---------|----------------|
| **AHI (events/h)**  | 7.1 ± 4.1                | 28.5 ± 11.5                 | <0.001* | 16.1 ± 13.4    |
| **Mean apnea time (s)** | 17 (14, 24)             | 24 (19, 30)                 | <0.001* | 20 (16, 27)    |
| **Maximum apnea time (s)** | 27 (19, 35)            | 40 (31, 61)                 | <0.001* | 31 (22, 47)    |
| **Lowest SaO2 (%)**  | 87.0 ± 3.7               | 81.6 ± 5.8                  | <0.001* | 84.7 ± 5.4     |
| **Mean SaO2 (%)**    | 95.4 ± 2.1               | 93.0 ± 2.4                  | <0.001* | 94.4 ± 2.5     |
| **ODI > 3%**         | 61.3 (30.9, 93.3)        | 23.3 (18.4, 31.1)           | <0.001* | 15.2 ± 13.5    |

Values are mean (± SD), median (interquartile range), or no. (%)

- BMI: body mass index, ACS: acute coronary syndrome, AF: atrial fibrillation, PO2: partial pressure of oxygen, PCO2: partial pressure of carbon dioxide, HDL: high-density lipoprotein, LDL: low-density lipoprotein, Hs-CRP: high-sensitivity C-reactive protein, LVEF: left ventricular ejection fraction, LVDD: left ventricular end diastolic diameter, LAD: left atrium diameter, AHI: apnea hypopnea index, SaO2: arterial oxygen saturation, ODI: oxygen desaturation index

* \( P < 0.05 \)
Relationship between Hs-CRP level and severity of OSA

A comparison of the severity of OSA between the normal Hs-CRP and elevated Hs-CRP groups (Fig. 3) showed that the proportion of patients with moderate-severe OSA was significantly higher in the elevated Hs-CRP group than in the normal Hs-CRP group (56% vs. 35%, \( P = 0.024 \)). Mean \( \Delta SaO_2 \) in the elevated Hs-CRP group was significantly lower than that in the normal Hs-CRP group (93.6 ± 2.6 vs. 94.8 ± 2.4%, \( P = 0.012 \)). Multivariate logistic regression showed that moderate-severe OSA was associated with elevated Hs-CRP level (dependent variable) (OR = 2.356, 95% CI 1.101–5.041, \( P = 0.027 \)) after adjusting sex, age, and BMI.

Correlation of Hs-CRP level with POAF, duration of hospitalization, and hospital cost

A comparison of postoperative clinical data between the normal Hs-CRP and elevated Hs-CRP groups (Fig. 4) showed that the proportion of patients with POAF was significantly higher in the elevated Hs-CRP group than in the normal Hs-CRP group (38% vs. 19%, \( P = 0.024 \)); duration of hospitalization (21.2 ± 7.1 vs. 16.0 ± 4.6 days, \( P < 0.001 \)) and hospital cost (143.1 ± 30.7 vs. 123.7 ± 21.8 × 1000 RMB, \( P < 0.001 \)) in the elevated Hs-CRP group were significantly higher than those in the normal Hs-CRP group.

Hs-CRP level was an independent risk factor for POAF (OR = 1.212, 95% CI 1.048–1.403, \( P = 0.01 \)) (Table 3). Table 4 showed that hypertension (\( B = -2.522 \), 95% CI \(-4.833 \) to \(-0.211 \), \( P = 0.033 \)), Hs-CRP level (\( B = 0.456 \), 95% CI \(0.202–0.710 \), \( P = 0.001 \)) and LVEF (\( B = -0.159 \), 95% CI \(-0.276 \) to \(-0.043 \), \( P = 0.008 \)) independently correlated with the duration of hospitalization; hypertension (\( B = -12.851 \), 95% CI \(-22.677 \) to \(-3.025 \), \( P = 0.011 \)), Hs-CRP level (\( B = 1.111 \), 95% CI \(0.031–2.192 \), \( P = 0.044 \)), and LVEF (\( B = -1.122 \), 95% CI \(-1.619 \) to \(-0.626 \), \( P < 0.001 \)) independently correlated with hospital costs.

Discussion

In this prospective cohort of 123 patients who underwent OPCABG, the prevalence of OSA was 42.3%. AHI, the criteria for severity of OSA, has limitations in predicting the prognosis of OPCABG. Hs-CRP level was closely related to the severity of OSA, and it independently correlated with POAF, duration of hospitalization and hospital cost.

OSA is closely related to CHD. A study showed that the prevalence of CHD in patients with OSA was 16.2%.

### Table 2 Comparison of intraoperative and postoperative clinical data between patients with absent-mild obstructive sleep apnea (OSA) and those with moderate-severe OSA who underwent off-pump coronary artery bypass grafting (OPCABG)

|                          | Absent-mild OSA (n = 71) | Moderate-severe OSA (n = 52) | \( P \) value | Total (n = 123) |
|--------------------------|--------------------------|-----------------------------|--------------|----------------|
| No. of performed grafting| 4.2 ± 0.6                | 4.2 ± 0.5                   | 0.849        | 4.2 ± 0.5      |
| Duration of surgery (min)| 233.6 ± 35.7             | 229.4 ± 34.7                | 0.525        | 231.8 ± 35.2   |
| MACCEs, n (%)            | 21 (30)                  | 11 (21)                     | 0.293        | 32 (26)        |
| Lung infection, n (%)    | 2 (3)                    | 2 (4)                       | 0.751        | 4 (3)          |
| POAF, n (%)              | 16 (23)                  | 16 (31)                     | 0.304        | 32 (26)        |
| Duration of ventilator use (h)| 21.1 ± 19.6         | 20.3 ± 13.3                 | 0.799        | 20.8 ± 17.2    |
| ICU stay (h)             | 34.0 ± 31.3              | 30.4 ± 22.8                 | 0.478        | 32.5 ± 28.0    |
| Duration of hospitalization (day)| 17.2 ± 5.7       | 18.8 ± 6.7                  | 0.176        | 17.9 ± 6.2     |
| Hospital cost (× 1000 RMB)| 128.4 ± 25.6            | 134.0 ± 28.7                | 0.260        | 130.8 ± 27.0   |

Values are mean ± (SD), median (interquartile range), or no. (%)

MACCEs: major adverse cardiac or cerebrovascular events, POAF: postoperative atrial fibrillation
and that of patients without OSA was 5.4% [7]; in a population with suspected CHD, the proportion of patients with moderate-severe OSA was 24%, four times higher than the prevalence in the normal population [8]. In the present study, we found that the proportion of patients with moderate-severe OSA was significantly higher than that of the previous study. Patients undergoing OPCABG with severe coronary artery disease were included in this study, which potentially indicated that OSA was a substantial risk factor for CHD.

CABG is the standard of care for patients with extensive CHD. Few studies showed that OSA might affect the prognosis of patients undergoing CABG. Uchôa et al. found that OSA significantly increased the long-term incidence of MACCEs (follow-up time of 4.5 years), revascularization rate, the proportion of angina attacks, and AF incidence in patients with CABG; however, there was no significant effect on the 30-day prognosis after CABG [9]. Another study found that AHI was an independent risk factor for increased duration of
hospitalization and postoperative circulatory fluctuation in patients with CABG [10]. In contrast, we found no significant difference in postoperative indicators between the moderate-severe OSA and absent-mild OSA groups. The possible reason for the discrepancy was that all patients included in our study underwent OPCABG, avoiding the effects of extracorporeal circulation, shortening the postoperative recovery cycle, which in turn reduced the short-term effect of OSA.

Evidence to identify the effect of OSA on the prognosis of OPCABG only using OSA classification is insufficient. OSA may affect the clinical outcome of CABG by influencing other indicators. For example, our previous study found that OSA might further affect the perioperative indicators such as the cardiac function [4]. In addition, biomarkers related to OSA and CHD may also be examined to predict more accurately the effect of OSA on CABG.

CRP is an acute phase reaction protein. Repeated hypoxia and inadequate ventilation in OSA could trigger oxidative stress and systemic inflammatory response, which could in turn enhance the synthesis and release of CRP [11]. Shamsuzzaman et al. showed that CRP has a significant linear correlation with AHI and is an independent influencing factor for OSA severity [12]. Moreover, inflammatory responses play key roles in the development of atherosclerosis. CRP, the product and mediator of inflammatory responses in atherosclerosis, is an important marker of endothelial dysfunction. Elevated CRP levels have been shown to be an independent risk factor for diseases such as myocardial infarction, peripheral vascular disease, and stroke [13]. Han et al. found that high CRP levels related to acute renal function injury, all-cause death, duration of hospitalization, and ICU stay after CABG [14].

Compared with the CRP, Hs-CRP extends the detection linear range from 3–200 to 0.005–0.10 mg/L, thereby making the determination of low-concentration CRP more accurate. Moreover, Hs-CRP has a long half-life, with no diurnal difference and no sex- or age-dependence and has a higher value in predicting the prognosis of cardiovascular and cerebrovascular diseases [15]. Previous studies have shown a relationship between Hs-CRP levels and OSA, nevertheless, these results are controversial because of obesity and various confounding factors [16]. In our study, we found that the Hs-CRP level was significantly increased in the moderate-severe OSA group, and there were significant correlations between Hs-CRP level and severity of OSA after adjusting sex, age, and BMI.

Hs-CRP plays an important role in predicting the prognosis of cardiovascular disease; nevertheless, only one report on the early effect of Hs-CRP on OPCABG has been conducted [17]. In the present study, we found that elevated Hs-CRP levels were significantly associated with increased AF incidence and duration of hospitalization. Our results also demonstrated that AF incidence, duration of hospitalization, and hospital costs were significantly higher in the elevated Hs-CRP group than in the normal group after OPCABG. Further regression analysis showed that Hs-CRP level was an independent risk factor for POAF and was independently correlated with the duration of hospitalization and hospital cost.

In addition, stability of respiratory regulation is an important factor in determining OSA severity [18]. Compared with the normal population, patients with OSA had significantly reduced respiratory center responses to low PO2 and high PCO2 during sleep, and the respiratory center response of some patients was also suppressed during wakefulness. Moreover, patients with OSA have long durations of apnea at night with short intervals. While hyperventilation occurs at the end of an apneic event, it is insufficient to clear the accumulated CO2, thereby resulting in hypercapnia or even type II respiratory failure. In this study, we found that the periods of apnea were significantly longer and the PCO2 level was significantly higher in the moderate-severe OSA group.

Table 3

| Covariate | Univariate | | | Multivariate | | |
|---|---|---|---|---|---|---|
| | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value |
| Male | 0.720 (0.288–1.800) | 0.482 | 1.645 (0.465–5.821) | 0.440 |
| Age (years) | 1.028 (0.980–1.078) | 0.260 | 1.021 (0.964–1.081) | 0.475 |
| BMI (kg/m2) | 1.043 (0.925–1.176) | 0.491 | 1.109 (0.957–1.284) | 0.168 |
| Hypertension | 1.507 (0.582–3.900) | 0.398 | 2.044 (0.659–6.340) | 0.216 |
| Diabetes | 0.668 (0.289–1.545) | 0.346 | 0.375 (0.132–1.061) | 0.064 |
| Smoking history | 0.430 (0.186–0.993) | 0.048* | 0.277 (0.096–0.804) | 0.018* |
| Hs-CRP (mg/L) | 1.166 (1.050–1.294) | 0.004* | 1.212 (1.048–1.403) | 0.010* |
| LVEF (%) | 0.949 (0.909–0.991) | 0.017* | 0.935 (0.881–0.994) | 0.031* |
| LAD (mm) | 1.095 (0.988–1.214) | 0.083 | 1.051 (0.926–1.194) | 0.440 |
| AHI (events/h) | 1.014 (0.985–1.044) | 0.342 | 0.994 (0.956–1.032) | 0.746 |

BMI: body mass index, PCO2: partial pressure of carbon dioxide, Hs-CRP: high-sensitivity C-reactive protein, LVEF: left ventricular ejection fraction, LAD: left atrium diameter, AHI: apnea hypopnea index

*P<0.05
than in the absent-mild OSA group when awake. Further study involving the change in PCO₂ and internal environment is needed.

In this study, the preoperative LVEF of patients with moderate-severe OSA was significantly lower than that of patients with absent-mild OSA. Previous studies also found that LVEF was independently related to moderate-severe OSA. The main mechanisms by which OSA affects cardiac function may be as follows [19, 20]: first, each respiratory obstruction event could result in an intrathoracic negative pressure of 60–70 cm H₂O, and hypoxia could cause pulmonary vasoconstriction, resulting in preload and afterload imbalance between the left and right ventricles; subsequently, myocardial oxygen consumption increases and myocardial ischemia occurs, which in turn alters cardiac function; second, the long-term repeated fluctuation of intrathoracic pressure could increase intraglomerular pressure variability, leading to impaired cardiac function; and finally, sympathetic hyperactivity affects all-day cardiopulmonary hemodynamics. In addition, hypopharyngeal edema due to decreased cardiac function could also promote the development of OSA.

CPAP remains the standard of care for patients with OSA, and evidence has revealed that it is correlated with a reduced inflammatory response [21]. Studies have confirmed that CPAP might result in decreased risk of repeat revascularization and cardiac death of patients with OSA after percutaneous coronary intervention (PCI) [22, 23]. However, we know little about the role of CPAP in improving prognosis of CABG. In consideration of our previous clinical practice, patient compliance and timing of CPAP treatment after CABG might be the key to curative effects. Additional trials evaluating the effects of CPAP in patients with OSA who underwent CABG are warranted.

Our study has the following limitations: first, it is a single-center study with a limited sample size; the results need to be validated using multi-center, large-sample studies. Second, we were unable to use polysomnography (PSG), which appears to offer a more accurate evaluation of OSA than does PG. In addition, PG may underestimate the OSA severity. PSG requires patients to sleep at the sleep center for more than 8 h. The sleep center in our hospital has not been provided with urgent response equipment and medical teams for patients with heart disease. All of our patients had severe coronary artery disease and were consequently at a high risk of emergent cardiac events. Therefore, we decided to use a portable PG monitor so that we could keep our patients in the cardiac surgery department for the assessment of OSA. Finally, we only analyzed Hs-CRP levels at one time point; thus, it remains unclear as to whether Hs-CRP level has the same predictive value at other time points.

| Covariate       | Dependent variable: duration of hospitalization | Dependent variable: hospital cost |
|-----------------|------------------------------------------------|----------------------------------|
|                 | Univariate                                      | Multivariate                     | Univariate                                      | Multivariate                     |
|                 | B (95% CI)                                      | P value                          | B (95% CI)                                      | P value                          |
| Male            | 0.68 (1.730 to 3.465)                           | 0.510                            | 1.867 (0.652 to 4.385)                          | 0.145                           |
| Age (years)     | −0.026 (−0.151 to 0.099)                        | 0.678                            | −0.015 (−0.134 to 0.103)                        | 0.796                           |
| BMÍ (kg/m²)     | −0.025 (−0.348 to 0.299)                        | 0.880                            | 0.116 (−0.181 to 0.413)                        | 0.441                           |
| Hypertension    | −2.131 (−4.570 to 0.309)                        | 0.086                            | −2.522 (−4.833 to 0.211)                       | 0.033*                          |
| Diabetes        | 0.457 (−1.784 to 2.697)                         | 0.687                            | −0.154 (−2.177 to 1.869)                       | 0.880                           |
| Hs−CRP (mg/L)   | 0.501 (0.251 to 0.751)                          | <0.001*                          | 0.456 (0.202 to 0.710)                         | 0.001*                          |
| LVEF (%)        | −0.235 (−0.347 to 0.122)                        | <0.001*                          | −0.159 (−0.276 to 0.043)                       | 0.008*                          |
| AHI (events/h)  | 0.112 (0.031 to 0.192)                          | 0.007*                           | 0.068 (−0.011 to 0.146)                        | 0.090                           |

BMI: body mass index, PCO₂: partial pressure of carbon dioxide, Hs-CRP: high-sensitivity C-reactive protein, LVEF: left ventricular ejection fraction, AHI: apnea hypopnea index

*P < 0.05
Conclusions
The results of our study suggested that OSA, particularly moderate-severe OSA, was highly prevalent in patients undergoing OPCABG. Compared with patients with absent-mild OSA, those with moderate-severe OSA had poorer cardiac function and higher PCO₂ and Hs-CRP levels. The Hs-CRP level was closely related to the severity of OSA and has an important predictive value for POAF, duration of hospitalization, and hospital cost among patients with OPCABG.

Abbreviations
OSA: Obstructive sleep apnea; Hs-CRP: High-sensitivity C-reactive protein; OPCABG: Off-pump coronary artery bypass grafting; PCO₂: Partial pressure of carbon dioxide; AHI: Apnea hypopnea index; ODI: Oxygen desaturation index; LVEF: Left ventricle ejection fraction; SaO₂: Arterial oxygen saturation; POAF: Post-CABG atrial fibrillation; CHD: Coronary heart disease; PG: Polygraphy; BMI: Body mass index; ICU: Intensive care unit; MACCE: Major adverse cardiac and cerebrovascular event; ACS: Acute coronary syndrome; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; LVDD: Left ventricular end diastolic diameter; LAD: Left atrium diameter.

Acknowledgements
The authors of this study would like to thank all the study participants. We thank Editage (https://app.editage.cn), for editing the English text of a draft of this manuscript.

Authors’ contributions
GMX and FKJ contributed equally to this article. Study concept and design: GMX, FKJ, YY. Acquisition, analysis, or interpretation of data: GMX, FKJ, YWY, WYX, YY. All authors read and approved the final manuscript.

Funding
This study was supported by the International Science and Technology Cooperation Program of China (No. 2015DFA30160), Beijing Municipal Science and Technology Commission (No. Z141100006014057), and National Natural Science Foundation of China (81770343). The funds were used to acquire portable sleep monitors for the study. The sponsor had no role in the design or conduct of this research.

Availability of data and material
The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Beijing Anzhen Hospital of Capital Medical University (Approval No. 201.3025). The study protocol, was explained to participants, all of whom signed informed consent.

Consent for publication
All study participants signed informed consent prior to participation.

Competing interests
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria, educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

Author details
1Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. 2Department of Otolaryngology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.

Received: 7 February 2021 Accepted: 20 July 2021 Published online: 31 July 2021

References
1. Senaratna CV, Jennifer LP, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev. 2017;34:70–81. https://doi.org/10.1016/j.smrv.2016.07.002.
2. Levy P, Ryan S, Oldenburg O, Parati G. Sleep apnoea and the heart. Eur Respir Rev. 2013;22:333–52. https://doi.org/10.1183/09059180.0004513.
3. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC scientific document group 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165. https://doi.org/10.1002/1097/0002-4636/ehj3.394.
4. Gao M, Wang P, Tang T, et al. Effects of obstructive sleep apnea hypopnea syndrome on postoperative complications in patients who undergo off-pump coronary artery bypass grafting. Sleep Breath. 2020. https://doi. org/10.1007/s11325-019-01990-5.
5. Rider PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol. 2016;67:712–23. https://doi.org/10.1016/j.jacc.2015.11.037.
6. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:479–504. https://doi.org/10.5664/jcsm.6506.
7. Peker Y, Carlson J, Hedner J. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. Eur Respir J. 2006;28:596–602. https://doi.org/10.1183/09031996.06.0017805.
8. Moee T, Rabben T, Wilkund U, Franklin KA, Eriksson P. Sleep-disordered breathing in men with coronary artery disease. Chest. 1996;109:659–63. https://doi.org/10.1378/chest.109.3.659.
9. Uchiha CH, Danzi-Saeres NJ, Nunes FS, et al. Impact of OSA on cardiovascular events after coronary artery bypass surgery. Chest. 2015;147:1352–60. https://doi.org/10.1378/chest.14-2152.
10. Tafelmeier M, Weizenegger T, Ripfel S, et al. Postoperative complications after elective coronary artery bypass grafting surgery in patients with sleep-disordered breathing. Clin Res Cardiol. 2018;107:1148–59. https://doi.org/10.1007/s10039-018-1289-0.
11. Guven SF, Turkkani MH, Ciftci B, Ciftci TU, Erdogan Y. The relationship between high-sensitivity C-reactive protein levels and the severity of obstructive sleep apnea. Sleep Breast. 2012;16:217–21. https://doi.org/10.1007/s11325-011-0492-2.
12. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated c-reactive protein in patients with obstructive sleep apnea. Circulation. 2002;105:2462–4. https://doi.org/10.1161/01.cir.0000018948.95175.03.
13. Szmikto PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108:1917–23. https://doi.org/10.1161/01.cir.0000088190.95415.9f.
14. Han SS, Kim DK, Kim S, Chin HJ, Chae DW, Na KY. C-reactive protein predicts acute kidney injury and death after coronary artery bypass grafting. Ann Thorac Surg. 2017;104:804–10. https://doi.org/10.1016/j.athoracsur.2017.01.075.
15. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 199945:2136–41.
16. Van der Touw T, Andronicos NM, Smart N. Is c-reactive protein elevated in obstructive sleep apnea? A systematic review and meta-analysis. Biomarkers. 2019;24:429–35.
17. Mirhosseini SJ, Forouzannia SK, Ali-Hassan-Sayegh S, Ravan HV, Abdollahi MH, Mozayan MR. Preoperative c-reactive protein can predict early clinical outcomes following elective off-pump CABG surgery in patients with severe left ventricle dysfunction. Saudi J Anaesth. 2012;6:327–31.
18. White DP. Advanced concepts in the pathophysiology of obstructive sleep apnea. Adv Otorhinolaryngol. 2017;80:7–16. https://doi.org/10.1159/000470522.
19. Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation. 1996;126:1495–510. https://doi.org/10.1161/circulationaha.111.070813.

20. Yumino D, Redolfi S, Ruttanamongkoon P, et al. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation. 2010;121:1598–605. https://doi.org/10.1161/circulationaha.109.902452.

21. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation. 2003;107:1129–34. https://doi.org/10.1161/circulationaha.103.011527.99976.18.

22. Wu X, Lu S, Yu X, et al. Treatment of OSA reduces the risk of repeat revascularization after percutaneous coronary intervention. Chest. 2015;147:708–18. https://doi.org/10.1378/chest.14-1634.

23. Cassar A, Morgenenthaler TI, Lennon RJ, et al. Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50:1310–4. https://doi.org/10.1016/j.jacc.2007.06.028.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.